Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Carbone

Showing results (181-190 of 190) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 190 results.
JHEP Reports : Innovation in Hepatology|October 9, 2024
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitisSurain B Roberts, Woo Jin Choi, Lawrence Worobetz, et al.
Journal of Hepatology|May 31, 2024
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantationAldo J Montano-Loza, Ellina Lytvyak, Gideon Hirschfield, et al.
Hepatology (Baltimore, Md.)|July 3, 2023
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?Christophe Corpechot, Sara Lemoinne, Pierre-Antoine Soret, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2024
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary CholangitisLaurent Lam, Pierre-Antoine Soret, Sara Lemoinne, et al.
Journal of Hepatology|October 5, 2025
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitisYu Jun Wong, Laurent Lam, Pierre-Antoine Soret, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 6, 2022
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acidAntonio De Vincentis, Daphne D'Amato, Laura Cristoferi, et al.
Gut|August 6, 2017
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitisRudi Alberts, Elisabeth M G de Vries, Elizabeth C Goode, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 23, 2024
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary CholangitisAntonio De Vincentis, Javier Ampuero, Francesca Terracciani, et al.
JHEP Reports : Innovation in Hepatology|July 21, 2025
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-worldFrancesca Terracciani, Antonio De Vincentis, Daphne D'Amato, et al.
Pageof 19

Showing results (181-190 of 190) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 190 results.
JHEP Reports : Innovation in Hepatology|October 9, 2024
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitisSurain B Roberts, Woo Jin Choi, Lawrence Worobetz, et al.
Journal of Hepatology|May 31, 2024
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantationAldo J Montano-Loza, Ellina Lytvyak, Gideon Hirschfield, et al.
Hepatology (Baltimore, Md.)|July 3, 2023
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?Christophe Corpechot, Sara Lemoinne, Pierre-Antoine Soret, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2024
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary CholangitisLaurent Lam, Pierre-Antoine Soret, Sara Lemoinne, et al.
Journal of Hepatology|October 5, 2025
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitisYu Jun Wong, Laurent Lam, Pierre-Antoine Soret, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 6, 2022
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acidAntonio De Vincentis, Daphne D'Amato, Laura Cristoferi, et al.
Gut|August 6, 2017
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitisRudi Alberts, Elisabeth M G de Vries, Elizabeth C Goode, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 23, 2024
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary CholangitisAntonio De Vincentis, Javier Ampuero, Francesca Terracciani, et al.
JHEP Reports : Innovation in Hepatology|July 21, 2025
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-worldFrancesca Terracciani, Antonio De Vincentis, Daphne D'Amato, et al.
Pageof 19